A Penn study in JAMA Health Forum compared 9 covering states with 36 that don't. Obesity-labeled scripts rose, but total GLP-1 use grew by less.
Recap by typeshit. Full story at The American Journal of Managed Care.
An explainer on talking to a provider about whether Wegovy fits you, plus a reminder that insurance may not pay for it.
Khunti shares real-world data on over a million UK adults using telehealth for obesity care, where 90% started on tirzepatide before a major price hike changed prescribing.
Polskie Radio reports a Wegovy price cut in China, coming soon after the drug's approval there. Tap through for the details.
Novo Nordisk is cutting what Wegovy costs in China, Polskie Radio reports. Tap through for the size of the cut and when it takes effect.
He describes peptides as short amino acid chains that act as signals, and stresses they are neither testosterone nor HGH.
In a SURPASS-CVOT subgroup with heart failure, the combined outcome hit 18.2% on tirzepatide vs 21.5%, mostly from fewer deaths. Authors call it hypothesis generating.
Loading…